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Abstract
Background
Standard care for HIV clinical practice has started focusing on age-related problems, but
despite this recent change physicians involved in HIV care do not often screen HIV patients
for frailty. Our aim was to construct three indexes from an HIV clinical database (i.e. Frailty
Index, (FI), HIV Index, (HIVI), and Protective Index (PI)) and to assess levels of frailty, HIV
severity and demographic and protective lifestyle factors among HIV patients.
Methods and findings
We included data from 1612 patients who attended an Italian HIV clinic between September
2016 and December2017 (mean±SD age: 53.1±8 years, 73.9% men).We used 92 routine
variables collected by physicians and other health care professionals to construct three
indexes: a 72-item FI (biometric, psychiatric, blood test, daily life activities, geriatric syn-
dromes and nutrition data), a 10-item HIVI (immunological, viral and therapeutics) and a 10-
item PI (income, education, social engagement, and lifestyle habits data)(the lower the FI
and HIVI scores, and the higher the PI scores, the lower the risk for participants).The FI,
HIVI and PI scores were 0.19±0.08, 0.48±0.17 and 0.62±0.13, respectively. Men had higher
FI (0.19±0.08 vs 0.18±0.08; p = 0.010) and lower HIVI (0.47±0.18 vs 0.50±0.15; p = 0.038)
scores than women. FI and HIVI scores both increased 1.9% per year of age (p < 0.001),
whereas the PI decreased 0.2% per year (p<0.050). In addition, the FI score increased
1.6% and the PI score decreased 0.5% per year of HIV infection (p < 0.001).
Conclusion
It is feasible to assess levels of frailty, HIV severity and protective lifestyle factors in HIV
patients using data from a clinical database. Frailty levels are high among HIV patients and
even higher among older patients and those with a long duration of HIV. Future studies
need to examine the ability of the three indices to predict adverse health outcomes such as
hospitalization and mortality.
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Introduction
The number of people older than 50 years living with HIV has increased from 76.000 in 1990
to 880.000 in 2016 in Western and Central Europe and North America [1]. This increase likely
reflects both higher rates of new diagnoses in people older than 50 years (7.4% in 1990 vs
15.6% in 2017) [2] and longer life expectancy due to better antiretroviral therapies [3]. An
important consequence is that more people who live with HIV are susceptible to common
geriatric syndromes which represents a challenge to conventional medical management. For
example, Green and colleagues [4] found that nearly half of people living with HIV were aged
50 or older, of whom 30–50% were affected by geriatric syndromes such as delirium, inconti-
nence and falls. This suggests that many people aging with HIV will be frail. Possible explana-
tions of this clinical phenomenon include the association between HIV specific factors,
chronic inflammation and dysregulation in the immune system along with a higher burden of
multiple concomitant noninfectious age-related comorbidities (e.g. cardiovascular disease,
chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus and osteopo-
rosis). These HANA (HIV-Associated-Non-AIDS) chronic conditions occur at a younger age
in HIV positive individuals compared with their HIV-counterparts and are associated with
higher rates of polypharmacy [5, 6], long-term ART toxicity, and changes in body fat and mus-
cle composition. They are also related to higher prevalence of behavioral and social risk factors
and worse socio-economic conditions in HIV positive patients [7–11]. Indeed, as reported by
Althoff and colleagues [12], HIV infected adults are at higher risk of myocardial infraction,
end stage renal disease and non-AIDS related cancer. To this point it is important to mention
that prevalence of risk behaviors, such as smoking, drinking and having an hypercaloric diet,
and comorbid conditions known to be well established cardiovascular risk factors such as
hypertension and dyslipidemia, is higher among people living with HIV [7–11, 13, 14]. Finally,
the authors of another cohort study (the AGEhIV Cohort Study) described higher prevalence
of age-associated comorbidities and respective risk factors when comparing HIV infected with
uninfected individuals [15].
Frail people experience a poor resolution of homeostasis even after minor stress events.
Frailty affects multiple organ systems, in particular, it has been associated with the develop-
ment of dementia and cognitive impairment [16, 17], lower levels of testosterone [18] and
higher levels of diurnal cortisol [19], sarcopenia [20], and immune system dysfunction that
makes the frail individual susceptible to recurrent infections [21]. Therefore, frailty can be
understood as a state of increased vulnerability among people of the same age which increases
risk of falls, disability, dependency, hospitalization, institutionalization, and death [16]. Many
clinical tools have been suggested to operationalize frailty. Among them, the Frailty Phenotype
and Frailty Index are the most applied in HIV medicine. Frailty Phenotype consists of five dif-
ferent items such as: self-reported weight loss and exhaustion, impairments at standard physi-
cal performance tests (walking gait speed, chair to stand test) and reduced physical activity
(evaluated through questionnaires) [22]. Another well-validated assessment tool in geriatric
medicine is the Frailty Index (FI). This tool has been applied in various clinical settings and is
based on the accumulation of health deficits approach [23]. Multiple health deficits or prob-
lems can be included in the FI such as signs and symptoms of age-related diseases, impair-
ments in activities of daily living, and comorbidities. Our group has previously studied
correlations and associations between these two health measures and clinical outcomes in
PLWH with similar results, however, FI showed stronger association with age, nadir CD4
count, comorbidities, falls, and disability [24]. Having a single score that is able to depict global
health status and trajectory with data collected in everyday practice and stored in clinical data-
bases might add useful information to clinical evaluation, beyond HIV related problems. A
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patient’s FI score is calculated by the ratio of health deficits present, dividing by all variables
evaluated, and it ranges from 0 to 1 [25]. The FI has been shown to predict adverse health out-
comes better than chronological age [26]. FIs developed in clinical settings other than HIV
medicine have been able to predict adverse outcomes such as mortality, morbidity, falls and
re-admission [27–29]. In the HIV field, our group has previously developed a 37-item FI based
mostly on blood test variables which was able to predict multimorbidity and mortality in HIV
positive people independent of markers of HIV disease severity [30]. Its use allows quantifica-
tion of the risk of adverse outcomes in people living with HIV. Accordingly, VACS Index,
which is a deficit accumulation index like the FI but was not developed to measure frailty, has
been utilized as a prognostic tool for survival [31]. In addition, another study has used an FI in
an HIV population to demonstrate association between frailty and higher levels of innate
immune activation [32].
In contemporary HIV care, initial goals of therapy such as undetectable HIV viral load and
the achievement of normal CD4+ T-cell count represent only the starting point of a general
health assessment [33]. Great concern has risen among HIV researchers and physicians due to
the lack of consensus on defining “geriatric age” in PLWH [4, 34, 35]. This is due to the higher
prevalence of geriatric syndromes and frailty at a younger age in PLWH. Therefore, it is
important to assess healthy aging in PLWH and to screen for frailty among these subjects.
Growing consensus suggests that implementing geriatric tools in clinical practice to depict
health trajectories across aging HIV cohorts may be useful [35]. This has led to the develop-
ment of a new discipline within HIV medicine termed “geriatric HIV medicine” [36]. As part
of an ongoing effort within our medical center to establish and promote geriatric HIV medi-
cine, we are collecting a wide range of clinical information across multiple domains such as
functional ability, cognition, physical and mental health, and socio-economic conditions. We
also decided to include FP items as different variables of this new FI, in order to finally merge
clinical information [37]. Indeed, exploring these domains represent the main innovation in
this new FI compared to the previous one which was, as mentioned above, more laboratory
oriented, and did not include many geriatric health variables.
The aim of our study was to construct three indices (i.e. Frailty Index, (FI), HIV Index,
(HIVI), and Protective Index (PI)) using data stored in our clinical database in order to assess
levels of frailty, HIV severity and demographic and protective lifestyle factors, which might
positively affect the life of individuals aging with HIV. We also assessed the construct validity
of these measures by evaluating their relationship with age and duration of HIV and by com-
paring the FI with other FIs validated in other community dwelling samples other than HIV.
Our future goal is to assess the predictive validity of these three indexes with the clinical end-
points of hospital admission, institutionalization, disability and death.
Methods
Design and study sample
The Modena HIV Metabolic Clinic is a multidisciplinary tertiary level care center which was
established in 2004 at The University of Modena and Reggio Emilia in Italy. Our clinic serves
patients with HIV from this region as well as across Italy. People from other regions are fol-
lowed by a physician in their hometown and receive clinical care annually. The Modena HIV
Metabolic Clinic uses a comprehensive assessment technique to examine and follow the meta-
bolic profiles, comorbidities and, more recently, the physical, emotional, cognitive and social
function of people living with HIV [38, 39]. Data are collected from blood tests, nuclear medi-
cine DXA scan, self-reported surveys, face-to-face interviews and clinical evaluation by physi-
cians, occupational therapists, dieticians and psychologists.
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In our study, we included data from 1612 consecutively recruited individuals who visited
the clinic from September 2016 to December2017. The study has been approved by the
Research Ethics Board of The University of Modena and Reggio Emilia and all participants
provided written informed consent.
Frailty index (FI)
An FI was built according to standard procedures described by Searle and colleagues [40]. Can-
didate deficits had to explore multiple health domains and organ systems such as blood tests,
emotional status, ability to handle daily activities, physical performances, nutrition and comor-
bidities. In addition, to be included in the FI, variables had to meet the following criteria: (i)
associated with age (not just attributes related to age, such as “greying hair”); (ii) increased prev-
alence with age; (iii)< 20% missing cases; (iii) when combined, measures had to capture multi-
ple organ dysfunction; (iiiii) ordinarily collected and stored in our clinical database at every visit
at MHMC. A total of 72 items across different domains were selected to construct the FI, which
included: urinary incontinence [41], hearing loss, falls and consequent fractures, bio-morpho-
logical data including systolic blood pressure, diastolic blood pressure, Body Mass Index, waist
circumference and sarcopenia [42], global nutrition, protein intake, central obesity, bone min-
eral density, self-reported unintentional weight loss, polypharmacy [43], gait speed, chair stand
test [44], 17 blood tests including hormone levels, 10 mental health questions measured with
the CES-D depression scale [45], 8 instrumental activities of daily living items [46, 47], 6 global
health status questions from the EQ5D5L scale [48], 4 respiratory function questions from the
St. George Respiratory questionnaire [49],and 8 comorbidities [50–54] (Table A in S1 Table).
Every variable was recoded into a 0 (no deficit) to 1 (presence/full deficit) score. Partici-
pants with mild or moderate impairment received a corresponding score that indicated the
proportion of the deficit (e.g. 0.25). Variables with less than 1% or more than 80% of the partic-
ipants having the health deficit were excluded. For example, a single IADL question concern-
ing the ability to handle medication had to be excluded because the deficit was present in less
than 1% of the study population [40]. The FI score was calculated as the sum of all deficits
scores divided by the sum of all variables evaluated for each participant. Scores ranged from 0
(absence of all deficits) to 1 (presence of all deficits). An FI was not calculated for participants
who had missing data for more than 20% of variables (14 missing variables; 105 participants,
6.5% of study population) [55]. The FI was used in the analysis as both continuous and dichot-
omous variable using the ()0.25 cut-point. This cut-off point was chosen because of the
nature of community dwelling samples [56]. FI scores in these populations tend to be lower
than clinical samples and are associated with age. This reflects the concept that levels of frailty
in community dwelling samples are lower than clinical ones [56].
HIV Index (HIVI)
An HIV Index (HIVI) was constructed using data collected as part of standard HIV clinical
practice according to current clinical national and international guidelines [57, 58]. Variables
included were: Centers for Disease Control and Prevention (CDC) 1993 revised classification
system for HIV infection [59], CD4+ Nadir, duration of HIV, time between diagnosis and
ARV start, 3rd line of ARV or more (as a surrogate of drug resistance or toxicity), HIV/AIDS
related cancers, presence or absence of lipodystrophy (using MACS criteria) [60], current CD4
+ T-cell count, HIV Viral load, and CD4-CD8 ratio. Each variable was recoded into a 0 (no
deficit) to 1(full expression of a deficit) (See Table B in S1 Table for HIVI variables coding).
Similar to the construction of the FI, the HIVI was calculated as the ratio between the number
of HIV-related health deficits present divided by the total number of HIV variables collected
Frailty, HIV and Protective Indexes
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(i.e. n = 10 HIV variables). HIVI was not calculated when participants had more than 20% of
missing data (n = 50 participants, 3.1% of study population). We also constructed a shorter
HIVI excluding duration of HIV so that we can investigate the relationship between HIVI and
duration of HIV. Since this is the first study where we attempted to create an HIV index, no
cut-off points have been established to differentiate grades of HIV disease severity.
Protective Index (PI)
To construct a PI we used the demographic and lifestyle variables routinely collected in The
Modena HIV Metabolic Clinic. In agreement with previous work from our research group [61]
we considered demographic and lifestyle choices as “protective factors”. Variables were chosen
from those included in common Social Vulnerability Indices [62, 63]. The following variables
were included in the PI: ethnicity, level of education, profession, income, physical activity [64],
injection drug use (past or current), marital status, domestic partnership, alcohol use (high con-
sumption: more than two glasses of wine/beer/spirits for five or more days per week; moderate
consumption: more than two glasses of wine/beer/spirits for two to five days a week; mild: more
than two glasses of wine/beer/spirits once a week or less), smoking habit (in order to clearly
identify individuals with no deficit, (never smokers) and to separate them from the rest of the
study population, we decided to lower the limit of “heavy smokers” from 20 pack-years to 10,
therefore our coding for smoking habit is as follows: high consumption: more than 10 pack-
years; moderate consumption: less than 10 pack- year; no consumption: never smokers). Eth-
nicity was recoded as “Italian vs non-Italian”. This is because language barriers can impede nor-
mal social functioning and can also influence access to health care and communication with
health care professionals. In addition, ethnicities other than Italian-Caucasian included in the
MHMC study population typically includes people from low-income countries, who marginal-
ized and live in poor socioeconomic environments. Each variable was recoded into a 0 (full defi-
cit) to 1(no deficit—protective) (See Table C in S1 Table for coding of variables). The PI was
not calculated when participants had more than 20% of missing data (n = 426 participants,
26.4% of study population). As with the HIVI, this is the first study to propose a PI in an HIV
population, no cut-points have been established to differentiate levels of ‘protection’.
Statistical analysis
We assessed the distribution of the three indices using histograms (Figs 1A, 2A and 3A).
Patients were divided into groups according to age (less than40, 41–50, 51–60 and>>60
years of age) and duration of HIV infection (10, 11–20,21–30, >30 years of infection). We
chose 0.25 as the FI cut-off point to determine frail individuals because 0.25 is the most com-
monly used FI cut point in the literature [65]. Prevalence of frailty and mean FI, HIVI, and PI
scores were calculated for the study population in relation to sex, age groups and duration of
HIV. Differences in mean index scores were examined using one-way ANOVA with adjust-
ment for multiple pair-wise comparisons. Differences in prevalence of frailty within age
groups, duration of HIV groups and sex were examined using non-parametric tests. Univariate
and multiple linear regression analyses were performed to investigate the relationship between
the index score with age (FI, HIVI, PI) and duration of HIV (FI, PI). SPSS version 24 (IBM
Corp, Armonk, NY, USA) was used to perform statistical analyses.
Results
Our study included 1612 people, the mean age was 53.1±8.0 years (median 53, range21-84
years) and most were men (79.3%, n = 1157). The median duration of HIV was 22.0 (0–32)
years, respectively. We were able to construct the FI for 1507 (93.5%) participants since the
Frailty, HIV and Protective Indexes
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Fig 1. FI characteristics. (A) Distribution of FI; (B) Association between FI and age.
https://doi.org/10.1371/journal.pone.0201394.g001
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Fig 2. HIVI characteristics. (A) Distribution of HIVI; (B) Association between FI and age.
https://doi.org/10.1371/journal.pone.0201394.g002
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Fig 3. PI characteristics. (A) Distribution of PI; (B) Association between FI and age.
https://doi.org/10.1371/journal.pone.0201394.g003
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patients with more than 20% missing variables were excluded. The lowest FI value was 0.02
and the highest was 0.55. Using the 0.25 FI cut-point we estimated that the prevalence of frailty
among the participants in our study was 20.2%. Both mean FI and prevalence of frailty
increased with age and with longer duration of HIV (p< 0.001) (Table 1 and Fig 1B). Men
had higher mean FI scores than did women (0.19±0.08 vs 0.18±0.08, p< 0.05). Univariate lin-
ear regression analysis between the natural log of FI (lnFI) and age showed a 1.9% increase in
lnFI score per year of life. Univariate linear regression analysis between the natural log of FI
(lnFI) and duration of HIV infection showed a 1.6% increase in lnFI score per year of infection
(p< 0.001).
A total of 1562 (96.7%) subjects met the criteria for the construction of HIVI. Mean±SD
HIVI was 0.48±0.17, median HIVI 0.48, the lowest value was 0.00 and the highest value was
0.92. Mean HIVI was higher in women than in men (0.50±0.15 vs 0.47±0.18, p< 0.05) and
HIVI increased with age (Fig 2B). Univariate linear regression analysis between the natural log
of HIVI and age showed an increase of 1.9% in lnHIVI per year (p< 0.001). Using the shorter
HIVI, which excluded duration of HIV from the index, we found that the lnHIVI
increased1.7% per year of infection (p< 0.001).
A total of 1186 (73.6%) subjects met the criteria for the construction of PI. Mean±SD PI
was 0.61±0.14). Median PI was 0.61, the lowest PI was 0.20 and the highest was 1.00. No statis-
tically significant difference in PI score between men and women was found (0.61±0.13 vs 0.61
±0.14 p> 0.05). The PI showed overall reduction with increasing age (0.2% of decrease in lnPI
per year of age, p = 0.019) (Fig 3B) and statistically significant differences in PI were found
between participants of 41–50 years of age and those 51–60 years (PI = 0.63±0.12 vs 0.59±0.13,
p<0.001). Differences in PI were also statistically significant when comparing those with the
longest duration of HIV (more than 30 years of infection) with the other 3 groups (p<0.05).
Univariate linear regression between natural log of PI and duration of HIV showed an average
decrease of 0.5% in the PI score per year of infection (p< 0.001).
Table 1. FI score and prevalence of frailty (FI0.25) according to sex, age and duration of HIV.
Mean ±SDFI N (%) of FI >0.25 Mean ±SDHIVI Mean ±SDPI
All patients (N = 1612) 0.19±0.08 325 (20.2%) 0.48±0.17 0.61±0.14
Sex
Men
(N = 1191)
0.19±0.08 238 (21.3%) 0.47±0.18 0.61±0.13
Women(N = 421) 0.18±0.08a 68 (17.5%) 0.50±0.15a 0.61±0.14
Age groups
40 years (N = 97) 0.12±0.06 1 (1.1%) 0.27±0.15 0.64±0.12
41–50 years (N = 422) 0.16±0.08a 49 (12.5%)a 0.42±0.18a 0.63±0.12
51–60 years (N = 829) 0.20±0.08a,b 183 (23.6%)a,b 0.52±0.15a,b 0.59±0.13b
>60 years (N = 264) 0.21±0.07a,b 73 (29.4%)a,b 0.50±0.17a,b 0.61±0.14
Duration of HIV
10 years (N = 215) 0.15±0.08 18 (8.9%) 0.28±0.14+ 0.64±0.12
11-20years (N = 366) 0.17±0.08a 45 (13.1%) 0.43±0.18+,a 0.62±0.12
21-30years (N = 690) 0.19±0.08a,b 149 (23%)a,b 0.51±0.15+,a,b 0.62±0.13
>30years (N = 294) 0.22±0.08a,b,c 85 (30.4%)a,b 0.50±0.15+,a,b,c 0.56±0.14a,b,c
astatistical significant different from first category
bstatistical significant different from second category
cstatistical significant different from third category
+shorter HIVI excluding duration of HIV
https://doi.org/10.1371/journal.pone.0201394.t001
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Discussion
We showed that it is feasible to assess levels of frailty, HIV severity and protective factors in
HIV patients using data collected from a clinical database. Levels of frailty and poor lifestyle
factors are high among HIV patients and even higher among older HIV positive patients and
those with a long duration of HIV. Since HIV negative and positive populations are different
in terms of comorbidities, geriatric syndromes and social and environmental factors [4, 18],
no age limit has been set yet to define the elder population among HIV positive individuals,
therefore, we decided to include all patients regardless of age. Due to the short period of obser-
vation, major clinical endpoints could not be used to validate these three health indexes, how-
ever, construct validation was performed, assessing the relationship with age and the rates of
health deficit accumulation in comparison with other FI’s validated with clinical endpoints as
hospital admission, institutionalization, disability and death [25, 27–29]. Considering our pop-
ulation is a community dwelling sample, levels of frailty were lower than those obtained from
clinical samples as expected [25], as with the association with age (0.7 increase in mean FI per
year), even if rates of deficit accumulation were slightly lower (1.9% of deficit accumulation
per year vs 2.9 in other longitudinal observational studies).
We have analyzed and collected data from multiple health domains involving different
health care professionals and obtaining 92 variables overall from 1612 patients. Not all
included variables are routinely collected across clinics, but most of them are easy to assess, at
least once per year. We were able to successfully build a 72-item FI, a 10-item HIV-Index, and
a 10-item Protective index, and analyze their correlations with sex, age and duration of HIV.
Compared to the previous 37-item FI validated in our clinic, this new FI explores more health
domains, including IADLs, geriatric syndromes, comorbidities, depression quotient, and mal-
nutrition, which are important comprehensive assessments. Distribution of the FI was right-
skewed, the prevalence of frailty increased with chronological age and longer duration of HIV,
and FI scores were higher in men than in women. We also created two new indices, one, the
HIVI, using HIV-specific variables from the sample population, and the other, the PI, using
demographic and lifestyle variables that could have a protective effect on individuals’ overall
health. The HIVI frequency displayed a right skewed distribution. Women had higher rates of
HIVI scores than men, and mean HIVI score increased across all four age groups. Duration of
HIV was originally included as an item in the HIVI but a shorter version of HIVI without
duration years of infection was calculated and found to be associated with duration of HIV.
On the contrary, PI was left-skewed and showed a statistically significant reduction when com-
paring people aged 41–50 years with people 51–60 years. The non-significant difference in PI
for the other two age groups could be related to the smaller sample size. Interestingly, rates of
protective factors accumulation reduced by 0.2 and 0.3 per year of age and HIV infection,
respectively. No sex differences were found in PI.
Strengths and limitations
Our results should be interpreted with caution. Due to the short period of study we were not
able to investigate the association between the FI, HIVI, and PI with common clinical out-
comes such as hospitalization and mortality. Further, variables included in our study were rou-
tinely collected as part of a comprehensive health assessment in our HIV clinic, but may not be
feasible to collect in general practices. The complexity of the data and variables analyzed, and
the broad age range of the study population would make it difficult to find a HIV negative con-
trol group for comparison, therefore the lack of a control group is another study limitation.
Our data showed trends similar to what has been reported in population studies; FI scores
increased with age, had a limit below 0.7, and a mean increase of 1.9% of deficit accumulation
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per year, which is slightly less than the average rates reported in community based longitudinal
observational studies (2.9%) [56]. This can be explained by the relatively younger median age
of the participants (53 years old, range 21–84) in our study compared to other study popula-
tions [15, 27, 66], which were analyzed to operationalize the FI. The sample population used to
construct the PI was smaller than the sample populations of both the FI and HIVI, because
socio-environmental data was collected a few months after the beginning of the study period.
Despite these limitations, our medical center continues to evaluate a high number of health
variables exploring biological, infectious, socio-environmental domains in a high-quality man-
ner and is the first to create three different indices to assess overall health in the HIV aging
population. Each of the FI, HIVI and PI show correlation with age (FI and HIVI had a positive
correlation with age whether PI had a negative correlation), and even more importantly with
duration of HIV infection, suggesting that duration of HIV infection might be a good predic-
tor of biological aging in HIV individuals. These health indices could be interpreted as mea-
sures of the general health and biological age of an individual. The large clinical sample, the
high number of variables included, the relatively few missing data, and the multidisciplinary
approach behind the concept of the three indices leads us to conclude that the FI, HIVI and PI
might represent important measures, which could be considered an integral part of a compre-
hensive health assessment in the HIV aging population.
Conclusions and clinical implications
Our study demonstrates that it is feasible to build health indexes from data stored in a clinical
database. With the available data we were able to create a 72-item FI exploring multiple health
domains, a 10 item HIV index and a 10 item Protective Index. Despite the great number of
variables analyzed, the vast majority of them, especially the HIV and socio-economic variables,
are easy to assess and can be obtained through questionnaires. Despite no cut-off points vali-
dated for HIVI and PI, these two indexes are based on health variables, which have important
clinical implications on patients’ health. Once built, health indexes are able to provide an over-
all score for the health of the patient and can also be used to track health changes over time.
Therefore, clinical utility of these health indexes lies in their ability to combine multiple vari-
ables across different health domains to create a single score.
Future studies are needed to evaluate causal relationships between HIVI, PI and FI and
how the HIVI and PI can predict the onset and progression of frailty. A key priority moving
forward will be to validate and operationalize these three indices with clinical outcomes in
external clinical settings. We aim to investigate this in depth in order to create a feasible clini-
cal assessment tool, which is able to rapidly and easily assess general health status in the HIV
aging population.
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